Pluri Inc. PLUR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-42.95
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.3M | -$22.6M | $654,000 | -$19.8M | -$865,000 |
| 2024 | $326,000 | -$20.9M | $322,000 | -$18.3M | $5.4M |
| 2023 | $287,000 | -$28.3M | $278,000 | -$23.1M | $15.3M |
| 2022 | $234,000 | -$41.2M | $234,000 | -$36.8M | $32.2M |
| 2021 | — | -$49.9M | — | -$31.3M | $57.2M |
| 2020 | $23,000 | -$29.2M | $23,000 | -$26.6M | $56.1M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -42.95 (distress)
- Working capital / assets -0.265
- Retained earnings / assets -11.453
- EBIT / assets -0.573
- Equity / liabilities -0.022
Source: SEC EDGAR filings · CIK 0001158780 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.